Bharat Serums gets DCGI nod to covid linked black fungus drug

Published On 2021-03-15 10:56 GMT | Update On 2021-03-15 10:56 GMT

New Delhi: A Mumbai-based bio-pharmaceutical firm has received approval from India's drug regulatory authority to use an anti-fungal drug for the treatment of black fungus or Mucormycosis, which recently saw an uprise among the patients recovering from the Covid-19.

The firm, Bharat Serums and Vaccines Limited, has become the first company in India to receive the approval from Drug Controller General of India (DCGI) to use anti-fungal medication -- Liposomal Amphotericin B or LAmB -- as a medical intervention in patients of Mucormycosis.

With a fatality rate of up to 80 per cent, Mucormycosis is a deadly invasive fungal infection which emerged as a 'new worry' for healthcare practitioners amid the Covid-19 pandemic. While it's cases have traditionally been low in India before the pandemic hit here, the instances started to rise among the people who recovered from the Covid-19.

Lately, many hospitals in India have reported the emergence of Mucormycosis cases in Covid-19 recovered patients. More than 50 cases were reported in Delhi hospitals alone in December last year.

The health experts said that the infection can turn aggressive within two days of its onset if not diagnosed on time and many a times, the patients have to let go of the organ it infects. Mucormycosis starts in the nasal area, sinuses, and quickly spreads to the eyes and the brain. If left untreated, this can result in a brain abscess, blindness or even death.

The infection predominantly occurs to immunocompromised people like those having poorly controlled diabetes, AIDS and certain cancers.

Those on immune suppressing medications or long-term steroid use are the most vulnerable to the Mucormycosis which also includes the patients of Covid-19 as steroids are used frequently to manage cytokine storms in the patients.

Vishwanath Swarup, COO, Bharat Serums & Vaccines (BSV), said that anti-fungal medication can prevent the patients suffering from black fungus from progressing the stage of surgery.

"BSV is indigenously developing and manufacturing the formulation of Amphotericin B including Liposomal Amphotericin B and Lipid Complex Amphotericin B - the anti-fungal medications that have been recommended for use in life-threatening fungal infections such as mucormycosis. Also, BSV is the first Indian company to get the regulatory approval of Liposomal Amphotericin B," he added.

Dr Swashraya Shah, BSV's Chief Medical officer, said that evidence suggests successful clinical recovery of patients suffering from Mucormycosis following the treatment with LAmB.

"Its treatment involves a combination of surgical removal of affected tissues and use of antifungal therapy, usually intravenous Liposomal Amphotericin B (LAmB). Several international clinical guidelines have recommended LAmB in the management of various invasive fungal infections including Mucormycosis. A few recently published reports mention successful clinical recovery of patients suffering from Mucormycosis following the treatment with LAmB," he noted.

Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Bharat Serums gets DCGI nod to covid linked black fungus drug

Similar News

Gland Pharma reports nearly 50% jump in Q1 profit

Aster DM Healthcare, India appoints Sudeep Dey as CIO, CISO

No Waiver for Faricimab: CDSCO Panel Asks Roche to Conduct Phase III Trial in India

Zydus Wellness incorporates wholly owned subsidiary in UK

Teva Pharma announces USFDA filing acceptance for Ajovy in Pediatric Episodic Migraine prevention

Sanofi completes acquisition of Vigil Neuroscience

NPPA Caps Prices of Ipratropium, Sodium Nitroprusside, Two Other Essential Drugs

Akum Pharma Asked to Submit Safety Data for Alzheimer's Drug Combo In Elderly Indian Patients